Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Meditech (MTCH) Viraplex - possible cancer treatment -- Ignore unavailable to you. Want to Upgrade?

To: Elliot who wrote (35)	6/7/1999 1:24:00 PM
From: OLD JAKE JUSTUS	Read Replies (1) \| Respond to of 39

The below was posted on another thread. It must have caught the eyes of some folks. This is just my guess: >>> Stock under 3cents that will run on Mon. stonecold [205.188.199.184] -------------------------------------------------------------------------------- MTCH was #9 on the OTC bb most active list on volume of almost 8 mill. MTCH has been developing Viraplex(R) for over 12 years, including testing done by the NCI(National Cancer Institute). Viraplex is for the treatment of certain types of cancer, including breast, prostate, and lung. MTCH is planning to introduce an over-the-counter topical version of its compound MTCH-24 for the treatment of Herpes Simplex I(cold sores). Management has had talks with a telemarketing group to telemarket the product to thousands of independent drug and convenience stores. They have also had talks with an internet group to handle sales direct to the customer. MTCH plans to sell its product through retail chain drug stores and various mass merchandisers.<<<